Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Views
    • Webinars
    • PharmSci360
  • Pharma 50
    • 2026 Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertisers
    • Advertise
    • PR Submissions
    • Eblast Submissions
  • SUBSCRIBE

Another Firm Comes Out Against Illumina Acquistion

By Drug Discovery Trends Editor | April 11, 2012

SAN DIEGO (AP) – Illumina Inc., which makes instruments for genetic analysis, said that a third shareholder advisory firm has recommended shareholders vote against Roche Holding AG’s offer to buy the company.

Glass, Lewis & Co. said Roche is simply pushing to complete a transaction on its terms regardless whether they reflect Illumina’s value or the board’s ability to carry out a stand-alone business plan.

The other two big independent proxy advisory firms, Institutional Shareholder Services Inc. and Egan-Jones Ratings Co., also sided with Illumina’s board last week.

Roche went public in January with an offer to buy Illumina for $5.7 billion, or $44.50 per share. Illumina said that price was too low, and Roche responded in late March by raising its offer to $51 per share.

Illumina, which is based in San Diego, said the new offer remains insufficient and accused Roche of trying to take advantage of a decline in the company’s share price in late 2010. The proxy advisers agreed.

“We find no cause for shareholders to support Roche’s candidates, nor do we find any reason for shareholders to accept such an expeditious engagement as appropriate in the context of multi-year lows in share price and valuation for Illumina,” Glass Lewis said in its report.

Illumina CEO Jay Flatley said he was confident that shareholders will reject Roche’s “hostile and opportunistic efforts to acquire Illumina at a grossly inadequate price.”

Illumina’s annual meeting is April 18.

Date: April 10, 2012
Source: Associated Press


Filed Under: Drug Discovery

 

Related Articles Read More >

NIH is reorganizing clinical trial funding by trial type instead of disease
Chemical formula of psilocybin
Psychedelic pioneer Compass files for FDA approval as rivals close in
Insilico’s AI-designed TEAD inhibitor shrank tumors in 4 of 22 mesothelioma patients; randomized Phase 2a planned for 2027
If Trump gets Europe to pay more for drugs, more new medicines could follow — eventually
“ddd
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in the drug discovery and development industry.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Drug Discovery and Development
  • MassDevice
  • DeviceTalks
  • Drug Delivery Business News
  • Medtech100 Index
  • Medical Design Sourcing
  • Medical Design & Outsourcing
  • Medical Tubing + Extrusion
  • Pharmaceutical Processing World
  • R&D World
  • Subscribe to our E-Newsletter
  • About Us
  • Contact Us

Copyright © 2026 Arrowfly LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of Arrowfly
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Views
    • Webinars
    • PharmSci360
  • Pharma 50
    • 2026 Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertisers
    • Advertise
    • PR Submissions
    • Eblast Submissions
  • SUBSCRIBE